Search results
Results from the WOW.Com Content Network
Since there were no approved generic alternatives to lomustine, patients were forced to absorb the price increases. The average age of people diagnosed with glioblastoma is 65, which included many Medicare patients who have Part D coverage. Under Part D coverage, patients are responsible for up to 25% of the price of a brand-name drug.
The main treatment for acral erythema is discontinuation of the offending drug, and symptomatic treatment to provide analgesia, lessen edema, and prevent superinfection. However, the treatment for the underlying cancer of the patient must not be neglected. Often, the discontinued drug can be substituted with another cancer drug or cancer treatment.
It is often referred to as "durable" medical equipment (DME) as it is intended to withstand repeated use by non-professionals or the patient, and is appropriate for use in the home. Medical supplies of an expendable nature, such as bandages, rubber gloves and irrigating kits are not considered by Medicare to be DME.
Starting Jan. 1, older adults on Medicare will spend no more than $2,000 a year on prescription drugs when a new price cap on out-of-pocket payments from the Inflation Reduction Act goes into effect.
In February 2016, comScore stated that Drugs.com was the sixth most popular health network receiving approximately 23 million visitors for the month, while Searchmetrics listed Drugs.com in the top 100 US websites for search visibility. [14] In April 2017, The Harris Poll listed Drugs.com as the Health Information Website Brand of the Year. [15]
Docetaxel (DTX or DXL), sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. [6] This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. [7]
Whole-person specialty care, a model where a comprehensive care team works together to coordinate personalized and individualized treatment, is offering renewed hope for patients.
This is based on 500,000 Medicare patients potentially receiving Aduhelm. To put this in perspective—in 2019, "total Medicare spending for all doctor-administered drugs reached $37 billion." [ 74 ] [ 75 ] For patients with applicable health insurance and/or Medicare, the drug is a tier 5 specialty drug.